Sanofi
(NASDAQ:SNY)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care produ...

Website: http://www.sanofi.com

Founded: 2004

Full Time Employees: 100,409

Sector: Healthcare

Industry: Drug Manufacturers-General

Healthcare

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-05-16	2022-04-04	2022-03-31	2021-12-31	2021-09-30	2021-07-30	2021-06-30	2021-05-11	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-05-22	2020-04-27	2020-02-06	2019-12-31	2019-07-29	2018-12-31	2018-07-31	2018-02-07	2017-12-31	2017-07-31	2017-04-30	2016-10-28	2016-07-29	2016-04-29	2016-02-09	2015-12-31	2015-07-31	2015-07-30	2015-04-30	2015-02-05	2014-10-28	2014-08-01	2014-07-31	2013-10-30	2013-08-02	2013-08-01	2012-07-27	2012-07-26	2011-12-31	2011-07-29	2010-12-31	2010-07-30	2009-12-31	2009-07-29	2008-12-31	2008-07-31	2008-02-11	2007-12-31	2007-08-02	2006-12-31	2006-05-05	2006-02-24	2005-12-31	2005-05-13	2005-03-01	2004-12-31	2004-09-14	2004-02-16	2003-12-31	2003-04-25	2003-04-15	2002-12-31

net sales	12,434	19,889	9,895	10,564	13,438	10,745	10,464		11,964	20,187	10,222		12,482	19,790	9,674	892.8	9,674		10,432	17,335	17,335	8,591	8,591		19,381	17,180	6,764	6,764	6,548		17,019		16,074	7,306		17,311	8,648	9,028	7,346	7,783	7,277		18,188	9,378	8,810	9,072	8,781	15,917	8,075	8,432	16,062	8,003	14,827	7,511,000,000		16,128		15,168		14,545		6,689	6,911		6,939		7,035	7,007		6,417,000,000	25,418,000,000		8,048,000,000	8,048,000,000		7,448,000,000	7,448,000,000
yoy	-7.47%	85.10%	-5.44%		12.32%	-46.77%	2.37%		-4.15%	2.01%	5.66%		29.03%		-7.27%	-94.85%	-44.19%		21.43%		-10.56%	-49.99%	27.01%		195.98%		-60.26%		-59.26%				85.87%	-19.07%		122.42%	18.84%		-59.61%	-17.01%	-17.40%		107.13%	-41.08%	9.10%	7.59%	-45.33%	98.89%	-45.54%	-100.00%		-50.38%		49518623.63%		10.88%		126.76%					-1.76%				-100.00%			-20.27%			8.06%
qoq	-37.48%	101.00%	-6.33%	-21.39%	25.06%	2.69%			-40.73%	97.49%			-36.93%	104.57%	983.56%	-90.77%			-39.82%	0.00%	101.78%	0.00%			12.81%	153.99%	0.00%	3.30%					120.01%			100.17%	-4.21%	22.90%	-5.61%	6.95%			93.94%	6.45%	-2.89%	3.31%	-44.83%	97.11%	-4.23%	-47.50%	100.70%	-46.02%	-100.00%									-3.21%					0.40%			-74.75%			0.00%			0.00%
other revenues	736	1,452	711	856	719	635	654		734	1,358	641		656	1,005	379		379		397	596	596	295	295		98	574	40	40	51		674		533	66		519	249	267	68	145	91		163	83	80	98	87	154	71	86	181	83	645	233,000,000		835		798		703		286	310		291		289	336		243,000,000
cost of sales	-3,412	-5,881	-2,889	-3,576	-4,085	-3,410	-3,439		-3,841	-6,347	-3,079		-3,831	-6,130	-2,880	-783.7	-2,880		-3,238	-5,541	-5,541	-2,684	-2,684		-5,153	-5,543	-1,745	-1,745	-1,830		-5,385		-5,265	-2,250		-5,670	-2,785	-2,776	-2,046	-2,447	-2,195										-5,214		-4,431	-2,249,000,000		-5,214				-3,619		-1,726	-1,964				-1,867	-1,901		-1,697,000,000
gross profit	9,758	15,460	7,717	7,844	10,072	7,970	7,679		8,857	15,198	7,784		9,307	14,665	7,173	109.1	7,173		7,591	12,390	12,390	6,202	6,202		14,326	12,211	5,059	5,059	4,769		12,308		11,342	5,122		12,160	6,112	6,519	5,368	5,481	5,173		12,627	6,523	6,104	6,129	6,004	10,947	5,538	5,644	11,029	5,414		5,495,000,000		11,749		11,861		11,629		5,249	5,257		5,390		5,457	5,442		4,963,000,000	19,376,000,000		6,620,000,000	6,620,000,000		6,070,000,000	6,070,000,000
yoy	-3.12%	93.98%	0.49%		13.72%	-47.56%	-1.35%		-4.84%	3.63%	8.52%		29.75%		-5.51%	-99.12%	-42.11%		22.40%		-13.51%	-49.21%	22.59%		200.40%		-58.90%		-57.95%				85.57%	-21.43%		121.86%	18.15%		-57.49%	-15.97%	-15.25%		110.31%	-40.41%	10.22%	8.59%	-45.56%	102.20%		-100.00%		-53.92%		46328202.84%		1.03%		125.97%					-3.67%				-100.00%			-25.03%			9.06%
qoq	-36.88%	100.34%	-1.62%	-22.12%	26.37%	3.79%			-41.72%	95.25%			-36.54%	104.45%	6474.70%	-98.48%			-38.73%	0.00%	99.77%	0.00%			17.32%	141.37%	0.00%	6.08%					121.44%			98.95%	-6.24%	21.44%	-2.06%	5.95%			93.58%	6.86%	-0.41%	2.08%	-45.15%	97.67%	-1.88%	-48.83%	103.71%											-0.15%					0.28%			-74.39%			0.00%			0.00%
gross margin %	78.48%	77.73%	77.99%	74.25%	74.95%	74.17%	73.38%	NaN%	74.03%	75.29%	76.15%	NaN%	74.56%	74.10%	74.15%	12.22%	74.15%	NaN%	72.77%	71.47%	71.47%	72.19%	72.19%	NaN%	73.92%	71.08%	74.79%	74.79%	72.83%	NaN%	72.32%	NaN%	70.56%	70.11%	NaN%	70.24%	70.68%	72.21%	73.07%	70.42%	71.09%	NaN%	69.42%	69.56%	69.28%	67.56%	68.37%	68.78%	68.58%	66.94%	68.67%	67.65%	0%	73.16%	NaN%	72.85%	NaN%	78.20%	NaN%	79.95%	NaN%	78.47%	76.07%	NaN%	77.68%	NaN%	77.57%	77.67%	NaN%	77.34%	76.23%	NaN%	82.26%	82.26%	NaN%	81.50%	81.50%
research and development expenses	-1,834	-3,717	-1,808	-2,257	-1,852	-1,704	-1,719		-1,663	-3,193	-1,563		-1,736	-3,147	-1,489	-17	-1,489		-1,443	-2,663	-2,663	-1,266	-1,266		-3,162	-2,692	-1,069	-1,069	-1,292		-2,972		-2,755	-1,278		-2,667	-1,309	-1,221	-1,138	-1,235	-1,214										-2,341		-2,051	-1,057,000,000		-2,297				-2,260		-1,091	-1,271				-1,046			-923,000,000	-3,961,000,000		-1,316,000,000	-1,316,000,000
selling and general expenses	-2,291	-4,506	-2,222	-2,648	-2,681	-2,655	-2,605		-2,579	-5,182	-2,607		-2,644	-4,953	-2,379		-2,379		-2,267	-4,530	-4,530	-2,194	-2,194		-3,665	-4,607	-1,253	-1,253	-1,484		-4,835		-4,819	-2,460		-5,046	-2,478	-2,274	-2,215	-2,212	-2,276										-4,438		-3,763	-1,939,000,000		-4,201				-3,627		-1,789	-1,996				-2,050			-1,920,000,000	-7,678,000,000		-2,477,000,000	-2,477,000,000
other operating income	297	533	331	363	187	173	444		388	617	436		983	416	390	4.2	390		259	409	409	267	267			281					273		323			173	60	34		217			83				47	116		56	347					191		236		450													248,000,000	248,000,000			190,000,000
other operating expenses	-1,600	-2,476	-1,158	-1,249	-1,158	-1,004	-1,006		-986	-1,422	-740		-803	-1,204	-655	-5.4	-655		-548	-709	-709	-368	-368			-693					-466		-165			-71	-26	-153		-124											-177					-168				-170
amortization of intangible assets	-461	-777	-399	-450	-479	-499	-562		-562	-1,035	-489		-460	-910	-449		-449		-385	-775	-775	-389	-389			-883					-1,116		-999			-990	-503	-403		-444											-1,543
impairment of intangible assets	-18	-210	-25	-200	-180	354	17			-15	-15		-1,586	-87	-5				1	-178	-178	-2				-323					-1,840		-101			-12		-21													-440
fair value remeasurement of contingent consideration	-56	-61		-22		-86	20			-26	-15		32	-17	4		4		5	-4	-4	-36	-36			54					190		10			-100	-36
restructuring costs and similar items	-172	-430	-105	-191	-256	-591	-740		-259	-547	-240		-374	-792	-175	-13.4	-175		-167	-327	-327	-156	-156			-758					-747		-607			-364	-119	-63
other gains and losses, and litigation		-57	-37		-10	-363	-79		22	-73	-88		5	-142	-18	-0.9	-18									136					317		-67			-7																				-517
operating income	3,623	3,759	2,285	1,185	3,635	1,595	1,449		3,211	4,322	2,463		2,724	3,829	2,397	-12.8	2,397		3,042	3,613	3,613	2,058	2,058			10,108					1,112		2,162			3,076	1,701	2,391		1,154			3,398		1,403		1,784	2,674		1,617	2,161					2,454		4,008		3,282		2,154	1,873		2,301		2,951	2,056		2,147,000,000
yoy	-0.33%	135.67%	57.69%		13.20%	-63.10%	-41.17%		17.88%	12.88%	2.75%		13.64%		-21.20%	-100.35%	-33.66%		47.81%			-79.64%											27.10%			166.55%							90.47%				-17.45%									-25.23%		86.07%					-36.53%
qoq	-3.62%	64.51%	92.83%	-67.40%	127.90%	10.08%			-25.71%	75.48%			-28.86%	59.74%	-18826.56%	-100.53%			-15.80%	0.00%	75.56%	0.00%														80.83%	-28.86%										-33.28%			-25.17%												15.00%					43.53%
operating margin %	29.14%	18.90%	23.09%	11.22%	27.05%	14.84%	13.85%	NaN%	26.84%	21.41%	24.10%	NaN%	21.82%	19.35%	24.78%	-1.43%	24.78%	NaN%	29.16%	20.84%	20.84%	23.96%	23.96%	NaN%	0%	58.84%	0%	0%	0%	NaN%	6.53%	NaN%	13.45%	0%	NaN%	17.77%	19.67%	26.48%	0%	14.83%	0%	NaN%	18.68%	0%	15.93%	0%	20.32%	16.80%	0%	19.18%	13.45%	0%	0%	0%	NaN%	15.22%	NaN%	26.42%	NaN%	22.56%	NaN%	32.20%	27.10%	NaN%	33.16%	NaN%	41.95%	29.34%	NaN%	33.46%	0%	NaN%	0%	0%	NaN%	0%	0%
financial expenses	-227	-361	-213	-235	-265	-333	-253		-318	-370	-168		-103	-189	-88	-2.1	-88		-87	-189	-189	-99	-99			-198					-244		-202			-218	-111	-261		-129											-311					-234				-151		-82	-73				-109	-104		-162,000,000
financial income	114	184	86	111	133	130	151		143	286	161		52	34	10	0.2	10		2	28	28	14	14			31					94		97			95	48	17		12			58		36		15	157		24	34					56		74		37		49	45		48		79	83		56,000,000			155,000,000	155,000,000		85,000,000	85,000,000
income before tax and associates and joint ventures	3,510		2,158	1,061	3,503	1,392	1,347		3,036		2,456		2,673		2,319		2,319		2,957			1,973	1,973													2,953	1,638	2,147		1,037			3,189		1,306		1,645	2,539		1,494	1,884					2,276
income tax expense	-680	-711	-481	-190	-737	-299	-164		-563	-730	-459		-601	-495	-332		-332		-609	-682	-682	-404	-404			-994					-13		-297			-610	-336	-460		-117											-356		-1,583			-472				-795		-628	-464				-832	-643		-650,000,000
share of profit of associates and joint ventures			42	9	78	24	-37		65		12		7		30		30					9	9													38
net income from continuing operations	2,828	2,956	1,719	880
net income from discontinued operations	-20	2,881	174	-185
net income	2,808	5,837	1,893	695	2,844	1,117	1,146		2,538	3,456	2,009		2,079	3,237	2,017	-15.8	2,017		2,343	2,796	2,796	1,578	1,578			9,301					1,065		1,835			6,802	5,735	1,703		1,113			2,384		1,055		1,221	1,922		1,248	1,532					2,360		3,568		2,869		1,605					2,173	1,444		1,415,000,000	1,706,000,000		2,076,000,000	2,076,000,000		1,759,000,000	1,759,000,000
yoy	-1.27%	422.56%	65.18%		12.06%	-67.68%	-42.96%		22.08%	6.77%	-0.40%		3.07%		-13.91%	-100.57%	-27.86%		48.48%			-83.03%											-68.00%			511.14%							95.25%				-20.30%									-17.74%		122.31%									-100.00%			-31.84%			18.02%
qoq	-51.89%	208.35%	172.37%	-75.56%	154.61%	-2.53%			-26.56%	72.03%			-35.77%	60.49%	-12865.82%	-100.78%			-16.20%	0.00%	77.19%	0.00%														18.61%	236.76%										-36.47%			-18.54%																	50.48%			-17.06%			0.00%			0.00%
net income margin %	22.58%	29.35%	19.13%	6.58%	21.16%	10.40%	10.95%	NaN%	21.21%	17.12%	19.65%	NaN%	16.66%	16.36%	20.85%	-1.77%	20.85%	NaN%	22.46%	16.13%	16.13%	18.37%	18.37%	NaN%	0%	54.14%	0%	0%	0%	NaN%	6.26%	NaN%	11.42%	0%	NaN%	39.29%	66.32%	18.86%	0%	14.30%	0%	NaN%	13.11%	0%	11.98%	0%	13.91%	12.08%	0%	14.80%	9.54%	0%	0%	0%	NaN%	14.63%	NaN%	23.52%	NaN%	19.72%	NaN%	23.99%	0%	NaN%	0%	NaN%	30.89%	20.61%	NaN%	22.05%	6.71%	NaN%	25.80%	25.80%	NaN%	23.62%	23.62%
net income attributable to non-controlling interests	6	25	21	12	29	4	13		13	26	14		3	53	8		8		26	20	20	12	12			20			-5		15		57	-29		64	34	29	-23	26	-39		59		32		31	61		35			-104	-49,000,000		136		147
net income attributable to equity holders of sanofi	2,802	5,812	1,872	683	2,815	1,113	1,133		2,525	3,430	1,995		2,076	3,184	2,009		2,009		2,317	2,776	2,776	1,566	1,566			9,281					1,050		1,778			6,738	5,701	1,674		1,087			2,325		1,023		1,190	1,861		1,213	1,448					2,224
average number of shares outstanding	1,218.1	1,225.5	1,233.9	1,253.6	1,253	1,250.1	1,248.8		1,253.2	1,249.9	1,249.3		1,253.5	1,250	1,249.2	90	1,249.2		1,254.5	1,250.3	1,250.3	1,249.3	1,249.3			1,251.7					1,247.2		1,247.8			1,260.3	1,262.4	1,288.5		1,288.4			1,307.2		1,308.4		1,313	1,317.2		1,323.5	1,323.9					1,308.6		1,305.8		1,305.5		1,306.5	1,335.3		1,351.9		1,344.4	1,338.5		1,334,550,189,000,000				702,745,208,000,000
basic earnings per share from continuing operations	2.32		1.38	0.69
basic earnings per share from discontinued operations	-0.02		0.14	-0.15
basic earnings per share	2.3	4.74	1.52	0.54
income before tax and investments accounted for using the equity method		3,582								4,238				3,674						3,452	3,452					9,941					962		2,057
share of profit from investments accounted for using the equity method		85								-52				58						26	26										116
average number of shares after dilution		1,230.7								1,254.5				1,255.3		90				1,255.6	1,255.6					1,258.2					1,254.7		1,254.9
•basic earnings per share from continuing operations		2.4
•basic earnings per share from discontinued operations		2.34
•diluted earnings per share from continuing operations		2.39
•diluted earnings per share from discontinued operations		2.33
diluted earnings per share		4.72
ifrs earnings per share					2.25	0.89	0.91		2.01		1.6		1.66		1.61		1.61		1.85			1.25	1.25														4.52	1.3
–basic earnings per share										2.74				2.55							2.22
–diluted earnings per share										2.73				2.54							2.21
selling and distribution expenses																-34
administrative and general expenses																-55.4
income before taxes																-14.6
income taxes																-1.2																																																							-614,000,000		-1,058,000,000	-1,058,000,000
attributable to equity holders of euroapi																-15.8
attributable to non-controlling interests																																																			84
- basic earnings per share																-0.18																																												2.02
- diluted earnings per share																-0.18																																												2.02
gain on regeneron investment as result of transaction completed on may 29th, 2020
gain on regeneron investment arising from transaction of may 29, 2020																										7,382
• basic earnings per share																				2.22
• diluted earnings per share																				2.21
as % of net sales																									73.9		74.8	74.8	72.8					-30.8					-27.9		-30.2			69.6		67.6			68.6			67.6		-29,900,000
other current operating income/expenses																									-339		-191	-191	-245												46					96			54			140		-165,000,000								74	15
share of profit/loss of associates* and joint ventures																									3		130	130											28		28
net income attributable to non controlling interests																									-25
business operating income																									7,138		2,668	2,668	1,879					1,485					2,023		1,718			2,566		2,443			2,145			2,017	5,527	2,408,000,000
share of profit/(loss) from investments accounted for using the equity method																										354
net income excluding the exchanged/held-for-exchange animal health business																										9,301					1,065		1,835			2,381
net income/(loss) of the exchanged/held-for-exchange animal health business
▪basic earnings per share																										7.41
▪basic earnings per share excluding the exchanged/held-for-exchange animal health business																										7.41
▪diluted earnings per share																										7.38
▪diluted earnings per share excluding the exchanged/held-for-exchange animal health business																										7.38
*
**
***
other includes the cost of global support functions (finance, human resources, information solution & technologies, sanofi business services, etc.…).
share of profit/loss of associates* and joint-ventures																													136					115
net income of the exchanged/held-for-exchange animal health business																																				4,421
– basic earnings per share																															0.84		1.42			5.35							1.78								1.09					1.7		2.62
– basic earnings per share excluding the exchanged/held-for-exchange animal health business																															0.84		1.42			1.84
– diluted earnings per share																															0.84		1.42			5.3							1.76								1.08					1.69		2.61
– diluted earnings per share excluding the exchanged/held-for-exchange animal health business																															0.84		1.42			1.82
share of profit of investments accounted for using the equity method																																	75
other operating income /expenses																																		15
average number of shares outstanding after dilution																																				1,270.6							1,322					1,333.8			1,340.5					1,313.3		1,309.3		1,306.5
other gains and losses and litigation
share of profit/loss of associates and joint ventures																																					6	6		93				30						29		3
net income excluding the held for exchange animal health business																																					1,308	1,693		1,013
net income from the held for exchange animal health business																																					4,427	10		100
earnings per share (in euros) excluding the held for exchange animal health business																																					1.01	1.29		0.77
fair value remeasurement of contingent consideration liabilities																																						-27		-29			71		1						-117					-66
other current operating income /expenses																																							3
restructuring costs																																								-500											-159					-467				-907		-179	-87					5		-13,000,000
earnings per share																																								0.84					0.78		0.91			0.92												1.23	1.09		1.24		1.62	1.08		1.06							2.42
financial income and expenses																																																					-227
tax rate**																																																	25
business net income																																												1,840		1,828			1,537			1,475	4,386
business earnings per share***																																																	1.17
share of profit/(loss) of associates and joint ventures																																																7			4
research & development expenses																																																																				-1,150
tax rate																																												25								21.1
business earnings per share																																												1.41								1.11
share of profit/loss of associates** and joint ventures																																														65
tax rate***																																														21
business earnings per share****																																														1.39
— basic earnings per share																																																1.41
— diluted earnings per share																																																1.4
share of profit/loss of associates* & joint ventures																																																	26
financial expense
other operating income and expenses																																																					-21														533	35		17,000,000
share of profit/(loss) of associates																																																					425			556		476
share of profit/loss of associates*																																																						123,000,000
amortization of intangibles																																																								-1,701				-1,805		-41	-45				-33	-28		-27,000,000
impairment of intangibles																																																								-69
operating income before restructuring, impairment of property, plant and equipment and intangibles, gains and losses on disposals, and litigation																																																										4,306		4,217
impairment of property, plant and equipment and intangibles																																																												-28
gains and losses on disposals, and litigation
income before tax and associates																																																										3,868		3,168		2,121	1,845		2,262		2,921	2,035
net income excluding the held-for-exchange merial business																																																										3,370
net income from the held-for-exchange merial business																																																										198
net income attributable to equity-holders of sanofi-aventis																																																										3,421
share of profit/loss of associates																																																												496		217	178		210		181	140		107,000,000
net income attributable to minority interests																																																												232
net income attributable to equity holders of the company																																																												2,637
operating income – current*																																																														2,402	1,960		2,329
impairment of pp&e and intangibles																																																														-69
gain/loss on disposals, and litigation
effective tax rate																																																														29.6					28.5	31.6		31,800,000
minority interests																																																														-105	-97		99		-97	-88		-83,000,000	-28,000,000		-3,000,000
reported tax rate																																																															-25.1		30.7
net income after minority interests																																																															1,462		1,678
other current operating income																																																																	87		119	69		77,000,000
other current operating expenses																																																																			-28	-30		-27,000,000
consolidated net income																																																																	1,777
operating income – current																																																																			2,419	2,020		2,143,000,000
net income before minority interests																																																																			2,270	1,532		1,498,000,000			2,079,000,000				1,846,000,000
€ million
selling & general expenses																																																																				-2,283
millions of euros
income before tax, associates & discontinued operations																																																																						2,041,000,000
discontinued operations
cost of goods sold																																																																							-6,042,000,000		-1,428,000,000	-1,428,000,000
other operating income/(expense)																																																																							426,000,000
operating profit																																																																							8,163,000,000		3,075,000,000	3,075,000,000		2,614,000,000	2,614,000,000
intangibles – amortization and impairment																																																																							-3,950,000,000		-129,000,000
financial income/(expense)																																																																							-599,000,000
exceptional items																																																																							-528,000,000		24,000,000	24,000,000		10,000,000	10,000,000
pre-tax income																																																																							3,086,000,000
income/(loss) from equity investees																																																																							88,000,000
goodwill amortization																																																																							-826,000,000		-8,000,000
adjusted earnings per share
income before tax and exceptional items																																																																									3,101,000,000			2,570,000,000	2,570,000,000
net income before income from equity investees, goodwill amortization and minority interests																																																																									2,067,000,000				1,834,000,000
income from equity investees																																																																									20,000,000	20,000,000			20,000,000
weighted-average shares outstanding																																																																								923,286,539,000,000	702,745,208,000,000		702,745,208,000,000	727,686,372,000,000	727,686,372,000,000
earnings per share, basic and diluted																																																																									2.95
intangibles — amortization and impairment																																																																										-129,000,000
exceptional items and goodwill amortization, net of income taxes and minority interests
net income before exceptional items and goodwill amortization																																																																										2,069,000,000		1,758,000,000
earnings per share (before exceptional items and goodwill amortization), in euros																																																																										2.94
earnings per share, in euros																																																																										2.95
in millions of euros
other operating income and charges																																																																												190,000,000
intangibles
income from equity investees net																																																																												20,000,000
exceptional items and goodwill amortization
earnings per share before exceptional items and goodwill amortization basic and diluted in euros																																																																												242
income before exceptional items and goodwill amortization, net of income taxes and minority interests																																																																													1,758
earnings per share before exceptional items and goodwill amortization																																																																													2.42

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-06-30	2023-12-31	2023-06-30	2022-12-31	2022-06-30	2022-04-04	2021-12-31	2021-06-30	2020-12-31	2020-06-30	2019-12-31	2019-07-29	2018-07-31	2017-12-31	2017-07-31	2016-12-31	2015-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2005-12-31	2004-12-31	2004-09-14	2004-02-16	2003-12-31	2003-04-25	2002-12-31

property, plant, and equipment – owned assets	9,698	9,574	9,819	10,091
right-of-use assets	1,483	1,433	1,533	1,510	1,616	1,654	1,723	1,815	1,875	45.6	1,948				1,300	1,105
intangible assets	68,867	60,714	63,809	66,255						26.8			62,785											13,747	15,260	19,182	30,229
non-current income tax assets	552	541	562	560	129	188	240	242	187		175	152	248
other non-current assets, investments in associates and joint-ventures and deferred tax assets	15,152	12,150	12,150	11,979
non-current assets	95,752	87,942	87,873	90,395	99,674	95,794	95,110	92,611	93,180	713.5	89,589	82,726	80,743		83,800	85,161	87,309	73,440	74,771	71,564	71,641	79,307	58,185	56,175	56,584	59,361	73,537
inventories, accounts receivable and other current assets	24,501	21,023	21,850	20,933									18,580
current income tax assets	497	397	447	724	295	391	353	374	538		612	623	1,208
cash and cash equivalents	8,906	15,359	7,991	7,441	6,795	8,710	7,993	12,736	6,899	10.3	10,098	9,722	13,915		9,427	6,742	7,493	10,315	10,877	10,273	9,148	4,124	6,465	4,692	4,226	1,711	1,249				152,000,000
assets held for sale	138	238	13,731	13,489																							676
current assets	34,042	37,017	44,019	42,587	30,079	30,655	29,976	34,026	28,360	905	30,564	29,502	33,703		28,611	25,314	23,936	26,352	27,071	26,687	24,928	20,791	20,043	17,532	15,403	12,553	13,121
total assets	129,794	124,959	131,892	132,982	129,755	126,464	125,353	126,722	121,826	1,618.5	120,242	112,321	114,529		112,736	110,545	112,778	99,826	101,870	104,672	102,321	100,165	85,264	80,049	71,987	71,914	86,658	76,755,000,000	10,557,000,000	9,749,000,000	17,424,000,000	85,000,000	9,459,000,000
property, plant and equipment owned					10,264		9,804		9,767			9,503
goodwill					50,080	49,404	49,243	49,892	50,555		48,056	44,979			44,519	44,418	44,828	40,264	40,964	40,287	39,557	38,079	31,932	29,733	28,163	27,199	30,234	23,475,000,000	128,000,000		4,788,000,000		134,000,000
other intangible assets					26,653	24,319	24,590	21,640	21,978		21,407	19,466			16,572	19,098	22,436	13,080	13,849	10,879	12,026	23,639	12,479						1,189,000,000		4,533,000,000		1,161,000,000
investments accounted for using the equity method					315	424	538	677	710		250	214			3,591	3,536	2,964	2,863
other non-current assets					3,333	3,218	2,992	3,095	3,312	9.7	3,127	2,699			2,667	2,261	3,133	3,364	2,928	2,820	2,725										250,000,000
deferred tax assets					7,284	6,427	5,980	5,381	4,796	45.3	4,598	4,240			5,434	5,137	4,478	4,290	4,556	4,669	4,714	3,633	3,051	2,912	2,920	2,912	3,095
inventories					10,609	9,666	9,970	8,960	9,366	569.5	8,715	9,261			7,994	8,423	7,364	6,816	7,246	6,892	6,516	6,051	5,020	4,444	3,590	3,729	3,430	3,058,000,000	844,000,000		799,000,000	11,000,000	823,000,000
accounts receivable					8,510	8,433	8,289	8,424	7,868	238.9	7,568	6,802			7,937	7,229	6,602	7,216	6,857	7,311	7,386	8,042	6,507	6,015	5,303	4,904	5,021	4,501,000,000	1,805,000,000		1,576,000,000	118,000,000	1,311,000,000
other current assets					3,870	3,455	3,371	3,532	3,689	75.5	3,571	3,094			3,253	2,920	2,477	2,005	2,091	2,211	1,767	2,401	2,000	2,104	1,881	2,126	2,434	2,476,000,000	1,197,000,000		923,000,000		854,000,000
assets held for sale or exchange					2	15	267	85	286		89	93	83		325	70	1,533	34	28	6,421	5,752	67	7,036	6,342
note
equity attributable to equity holders of sanofi					72,690	74,040	72,629	74,784	70,951		68,681	63,237			58,934	56,353	56,197	58,089	57,631		58,049
equity attributable to non-controlling interests					307	313	318	368	353		350	127			174	165	164	169	161		161
total equity					72,997	74,353	72,947	75,152	71,304	1,011.4	69,031	63,364			59,108	56,518	56,361	58,258	57,792		58,210			48,446	45,071	44,719
long-term debt					12,503	14,347	14,241	14,857	15,942		17,123	17,935			20,131	21,087	22,788	14,326	15,186		13,118			5,961	4,173	3,734		8,638,000,000	49,000,000		53,000,000		65,000,000
non-current lease liabilities					1,733	1,755	1,839	1,904	2,001	18.7	1,839	1,242			987	958
non-current liabilities related to business combinations and to non-controlling interests					527	501	563	674	742		577	247			508	739	1,018	1,026	1,287
non-current provisions and other non-current liabilities					8,219	7,602	7,088	6,341	6,181		6,721	7,022			9,321	9,099	8,949	9,154
non-current income tax liabilities					1,949	1,842	1,928	1,979	2,029		2,039	1,692
deferred tax liabilities					1,800	1,857	1,950	1,841	1,550	5.6	1,617	1,674			2,294	2,938	3,784	1,605	2,128		2,895			4,933	5,668	6,935
non-current liabilities					26,731	27,904	27,609	27,596	28,445	219.4	29,916	29,812			33,241	34,821	36,539	26,111	27,013		26,303			19,205	17,571	17,526
accounts payable					7,433	7,328	7,365	6,813	6,558	189.6	6,180	5,374			5,313	5,082	4,582	4,633	4,303		3,817			2,654	2,791	2,749		2,765,000,000	765,000,000		657,000,000	16,000,000	596,000,000
current liabilities related to business combinations and to non-controlling interests					201	208	154	105	90		137	200			292	273	450	343	234
current provisions and other current liabilities					12,746	13,741	11,917	12,021	11,675		11,217	10,493			9,961	9,200	8,422	9,206
current income tax liabilities					132	597	377	574	443		309	588
current lease liabilities					279	275	253	277	231	4	269	247			261	240
short-term debt and current portion of long-term debt					9,236	2,045	4,694	4,174	3,063		3,183	2,225			4,554	4,411	6,153	1,275	3,241		3,436			2,866	1,833	2,207
current liabilities					30,027	24,194	24,760	23,964	22,060	387.7	21,295	19,127			20,381	19,206	19,607	15,457	17,055		16,825			10,965	9,345	9,669
liabilities related to assets held for sale or exchange						13	37	10	17			18			6		271		10		983			1,433
total equity and liabilities					129,755	126,464	125,353	126,722	121,826	1,618.5	120,242	112,321			112,736	110,545	112,778	99,826
property, plant and equipment						10,160		9,869		586.1	10,028				9,717	9,606	9,470	9,579	9,633	10,019	9,943	10,750	8,155	7,830	6,961	6,538	6,184	5,886,000,000			1,427,000,000
other current financial assets										10.9
equity attributable to equity holders of euroapi										1,011.4
provisions										195
other non-current liabilities																															913,000,000
other current liabilities										192.7									9,277		9,442			5,445	4,721	4,713		4,852,000,000	1,813,000,000		1,614,000,000	68,000,000	1,599,000,000
short-term debt and other financial liabilities										1.4
property, plant and equipment leased - right-of-use assets												1,473
property, plant and equipment - owned assets													9,365
right of use													1,198
non-current financial assets & investments in associates and deferred tax assets													7,147
net income attributable to equity holders of sanofi														9,281
net (income)/loss of the exchanged/held-for-exchange animal health business
non-controlling interests														20
share of undistributed earnings from investments accounted for using the equity method														-327
depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets														2,013
gains and losses on disposals of non-current assets, net of tax														-177
gain on regeneron investment arising from transaction of may 29, 2020, net of tax														-6,870
net change in deferred taxes														-296
net change in non-current provisions and other non-current liabilities														317
cost of employee benefits														168
impact of the workdown of acquired inventories remeasured at fair value														36
other profit or loss items with no cash effect														155
operating cash flow before changes in working capital and excluding the exchanged/held-for-exchange animal health business														4,320
(increase)/decrease in inventories														-1,023
(increase)/decrease in accounts receivable														516
increase/(decrease) in accounts payable														-325
net change in other current assets and other current liabilities														438
net cash provided by/														3,926
acquisitions of property, plant and equipment and intangible assets														-682
acquisitions of consolidated undertakings and investments accounted for using the equity method														-2,360
acquisitions of other equity investments														-17
proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax														709
net proceeds from sale of regeneron shares on may 29, 2020														10,512
net change in other non-current assets														-87
net cash provided by/(used in) investing activities excluding the exchanged/held-for-exchange animal health business														8,075
net cash inflow/(outflow) from the exchange of the animal health business for bi’s consumer healthcare business
issuance of sanofi shares														38
dividends paid:
▪ to shareholders of sanofi														-3,937
▪to non-controlling interests														-4
payments received/(made) on changes of ownership interest in a subsidiary without loss of control
additional long-term debt contracted														2,014
repayments of long-term debt														-3,954
repayment of lease liabilities														-121
net change in short-term debt														923
acquisitions of treasury shares														-361
disposals of treasury shares
net cash provided by/(used in) financing activities excluding the exchanged/held-for-exchange animal health business														-5,402
investments in associates and joint ventures																			2,841	2,890	2,676	807	924
provisions and other non-current liabilities																			8,412		9,169			8,311	7,730	6,857
total liabilities and equity																			101,870		102,321
consolidated balance sheets – liabilities and equity
current financial assets																					111	173	51
non-current liabilities relating to business combinations and to non-controlling interests																					1,121
current liabilities relating to business combinations and to non-controlling interests																					130
assets
non-current financial assets																						2,399	1,644
in accordance with ifrs 3 (business combinations), sanofi-aventis adjusted the values of certain identifiable assets and liabilities of merial during the purchase price allocation period (see note d.1.).
investments in associates																								955	2,459	2,493	2,477
financial assets — non-current																								998	821
financial assets — current																								277	403
liabilities & equity
equity attributable to equity holders of the company																								48,188	44,866	44,542
minority interests																								258	205	177		359,000,000	16,000,000		18,000,000		17,000,000
total liabilities & equity																								80,049	71,987	71,914
liabilities related to assets held for sale
financial assets – non-current																										1,037	1,318
financial assets – current																										83	311
as allowed under ifrs 3, sanofi-aventis has revised certain preliminary estimates of the aventis purchase price allocation within the permitted 12-month period.
patents, licenses and other intangibles																												29,600,000,000
assets - sum																												53,075,000,000					1,295,000,000
long-term investments
equity investees																												2,404,000,000
other investments and advances																												11,000,000
other long-term investments																												929,000,000	105,000,000				73,000,000
total fixed assets																												62,305,000,000	3,083,000,000	2,712,000,000			2,899,000,000
deferred income taxes																												1,925,000,000	410,000,000	472,000,000	362,000,000		484,000,000
short-term investments and deposits																												958,000,000	3,084,000,000		2,614,000,000		2,944,000,000
cash																												1,532,000,000	134,000,000				144,000,000
in millions of euros
liabilities and shareholders’ equity
shareholders’ equity																															12,736,000,000	1,000,000
share capital																												2,823,000,000	1,466,000,000				1,465,000,000
additional paid in capital and reserves																												39,377,000,000	4,571,000,000				2,971,000,000
net income for the period																													1,138,000,000				1,759,000,000
cumulative translation adjustment																													-341,000,000
total shareholders’ equity																												35,574,000,000	6,834,000,000				6,035,000,000
other equity instruments																												16,000,000
provisions and other long-term liabilities																												5,768,000,000	795,000,000				786,000,000
short-term debt																												7,388,000,000	274,000,000				351,000,000
total liabilities and shareholders’ equity																												76,755,000,000	10,557,000,000		17,424,000,000	85,000,000	9,459,000,000
gross																													2,413,000,000				1,989,000,000
accumulated depreciation																													-904,000,000
net																													1,509,000,000				1,395,000,000
investments in/advances to equity investees																													145,000,000				109,000,000
investments in/advances to non-consolidated companies																													7,000,000				27,000,000
liabilities and shareholders' equity
inventories, accounts receivable & other current assets																														3,187,000,000
short-term investments and deposits, cash																														3,378,000,000
total – current assets																															6,426,000,000
current portion of long-term debt																															315,000,000
total – current liabilities																															2,586,000,000
total – liabilities																															2,084,000,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-06-30	2023-06-30	2022-06-30	2022-04-04	2021-06-30	2019-07-29	2018-07-31	2017-07-31

business net income	7,699		2,212
depreciation, amortization and impairment of property, plant and equipment and software	1,080		349
other items	-796		-380
operating cash flow	7,983		2,181
changes in working capital	136		-96
acquisitions of property, plant and equipment and software	-1,288		-490
free cash flow before restructuring, acquisitions, and disposals	6,831		1,594
acquisitions of intangibles assets, investments, and other long-term financial assets2	-1,415		-623
restructuring costs and similar items paid	-491		-287
proceeds from disposals of property, plant, and equipment, intangible assets, and other non-current assets net of taxes2	527		344
free cash flow	5,452		1,029
acquisitions3	-9,546
issuance of sanofi shares	170	29	22	21	31	40		23	58	19	99
acquisition of treasury shares and related tax effect	-4,128
dividends paid to shareholders of sanofi	-4,772
net cash inflow from the opella transaction	10,662	10,742
net cash provided by/(used in) the discontinued opella business	136		161
change in net debt before opella reclassification to “assets held-for-sale”	-2,383		-2,315
opella net debt reclassified to held for sale as of december 31, 2024	98
change in net debt	-2,285		-2,472
beginning of period	8,772		8,772
closing of net debt	11,057		11,245
net cash provided by/(used in) continuing operating activities	7,118		1,908
net cash provided by/(used in) operating activities of the discontinued opella business	187		185
net cash provided by/(used in) operating activities	7,305		2,093
net cash provided by/(used in) continuing investing activities	-10,937		-767
net cash provided by/(used in) investing activities of the discontinued opella business	-36
net cash provided by/(used in) investing activities	-316		-776
net cash provided by/(used in) continuing financing activities	-5,589		-584
net cash provided by/(used in) financing activities of the discontinued opella business	-48
net cash provided by/(used in) financing activities	-5,637		-592
impact of exchange rates on cash and cash equivalents	-54	-42	-20	-14	-19	40		8	12	-9	-47
cash and cash equivalents reported as held for sale as of december 31, 2024	167
net change in cash and cash equivalents	1,465	7,918	550	-1,915	-4,743	-3,199	10.3	-4,193	-183	-2,822	604
cash and cash equivalents, beginning of period	7,441	7,441		8,710	12,736	10,098		13,915	6,925	10,315	10,273
cash and cash equivalents, end of period	8,906	15,359		6,795	7,993	6,899	10.3	9,722	6,742	7,493	10,877
net income attributable to equity holders of sanofi		5,812		2,246	3,430	3,184		2,776	1,050	1,778	6,738
net loss from the discontinued opella business		-2,881
non-controlling interests		25		17	26	53		20
share of undistributed earnings from investments accounted for using the equity method		-15		110	196	-53		-8	-82	-59
depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets		1,779		1,445	1,838	1,820		1,726	3,779
gains and losses on disposals of non-current assets, net of tax		-266		-279	-307	-368		-105	-63	-217	-79
net change in deferred taxes		-539		-780	-446	-404	-17.1	-134	-818	-330	-269
net change in non-current provisions and other non-current liabilities		-212		1,087	-716	436	-2.2	-151	-27	-56
cost of employee benefits		171		173	160	144	1.8	134	131	152	126
impact of the workdown of acquired inventories remeasured at fair value				19	5	3			3	100	176
other profit or loss items with no cash effect on cash flows generated by operating activities		106		26	196	52
operating cash flow before changes in working capital		3,980		4,064	4,382	4,867	42.6	4,219
decrease in inventories		-635		-886	-1,174	-1,122	14	-821	-934	-627	-502
decrease in accounts receivable		-785		14	-215	18	-131	751	90	571	150
increase in accounts payable		187		82	497	111	88.9	-89	-49	-219	110
net change in other current assets and other current liabilities		620		-1,851	73	-49	57.2	694	96	-1,232
net cash from continuing operating activities		3,367
net cash from operating activities of the discontinued opella business		188
net cash from operating activities		3,555		1,423	3,563	3,825	71.5	4,754
capital expenditures		0		0	0	0	0	0
free cash flows		3,555		1,423	3,563	3,825	71.5	4,754
acquisitions of property, plant and equipment and intangible assets		-1,420		-1,886	-930	-974	-88.6	-1,018	-841	-823	-998
acquisitions of consolidated undertakings and investments accounted for using the equity method		-538		-1,885	-2,465	-977		-1,520	-134	-12,784
acquisitions of other equity investments		-423		-208	-56	-110		-71	-24	-32
proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax		434		607	578	544	0.7	299	867	486	440
disposals of consolidated undertakings and investments accounted for using the equity method					15	101
net change in other non-current assets		-32		-41	-215	-43		-29	-33
net cash from continuing investing activities		-1,979
net cash from investing activities of the discontinued opella business		-36
net cash from investing activities		8,727		-3,413	-3,073	-1,459	-87.9	-2,339
dividends paid:
• to equity holders of sanofi		-4,772
• to non-controlling interests		-27
additional long-term debt contracted		2,993				1,497		1	1,994	9,674	1
repayments of long-term debt		-1,859		-637	-2,680	-2,694		-2,211	-1,261	-25	-7
repayment of lease liabilities		-124		-144	-127	-137	-2.5	-106	-135
net change in short-term debt and other financial instruments		3,322		5,886	2,431	286		-134
acquisitions of treasury shares and related tax effect		-4,003
net cash from continuing financing activities		-4,441
net cash from financing activities of the discontinued opella business		-48
net cash from financing activities		-4,489		89	-5,214	-5,605	26.5	-6,616
cash and cash equivalents reclassified to assets held for sale as of december 31, 2024		167
acquisition of treasury shares			-3,609
impact on net debt of the reclassification of opella to “assets held-for-sale”			-157
impact on cash and cash equivalents of the reclassification of the opella business to "assets held for sale"			-154
cash and cash equivalent, beginning of period			7,441
cash and cash equivalent, end of period			7,991
▪ to equity holders of sanofi				-4,704	-4,454	-4,168
▪to non-controlling interests				-31	-49	-69		-41
payments received/(made) on changes of ownership interest in a subsidiary without loss of control					-3					-45
acquisitions of treasury shares				-302	-363	-360		-140	-12	-730	-1,700
disposal of consolidated undertakings and investments accounted for using the equity method, net of tax
•to shareholders of sanofi
•to non-controlling interests
repayments of lease liabilities
gain on regeneron investment arising from transaction of may 29, 2020, net of tax
(increase)/decrease in inventories
(increase)/decrease in accounts receivable
increase/(decrease) in accounts payable
net cash provided by/
net proceeds from sale of regeneron shares on may 29, 2020
f-8
net income attributable to equity holders of euroapi							-15.8
depreciation, amortization and impairment of property, plant and equipment, intangible assets and right-of-use assets							76
losses on asset disposals, net of tax
other profit or loss items with no cash effect							-0.1	-39	-12
capital increase
dividends paid to equity holders of euroapi
net change in short-term debt							1.3		-13	3,383	173
net contribution of sanofi equity holders to the consolidated group							27.8
net loss of the exchanged/held-for-exchange animal health business											-4,421
operating cash flow before changes in working capital and excluding the exchanged/held-for-exchange animal health business									3,976	3,281	3,832
net cash from operating activities excluding the exchanged/held-for-exchange animal health business									3,179	1,773	2,556
net cash from investing activities excluding the exchanged/held-for-exchange animal health business									-165	-13,085	-1,062
net cash inflow from the exchange of the animal health business for bi’s consumer healthcare business										5	4,349
net cash from financing activities excluding the exchanged/held-for-exchange animal health business									-3,209	8,494	-5,192
▪ to shareholders of sanofi								-4,008
net (income)/loss of the exchanged/held-for-exchange animal health business
non-controlling interests, excluding bms									15	15	21
net cash provided by/(used in) investing activities excluding the exchanged/held-for-exchange animal health business
•to non-controlling interests, excluding bms
net cash provided by/(used in) financing activities excluding the exchanged/held-for-exchange animal health business
sanofi form 20-f 2020 \|
net cash inflow/(outflow) from the exchange of the animal health business for bi’s consumer healthcare business
disposals of treasury shares									3
2020 half-year financial report - sanofi
▪to shareholders of sanofi
▪to non-controlling interests, excluding bms
• to shareholders of sanofi									-3,834	-3,773	-3,710
• to non-controlling interests, excluding bms									-9	-10	-11
depreciation, amortization and impairment of property, plant and equipment and intangible assets										1,779	1,762
other profit or loss items with no cash impact										119
net cash from operating activities of the exchanged/held-for-exchange animal health business
net change in loans and other financial assets										67	-18
net cash from investing activities of the exchanged/held-for-exchange animal health business
disposals of treasury shares, net of tax
net cash from financing activities of the exchanged/held-for-exchange animal health business
share of undistributed earnings of associates and joint ventures											-9
net change in provisions											-204
unrealized losses recognized in income											-9
net change in other current assets, current financial assets and other current liabilities											-1,034
acquisitions of investments in consolidated undertakings, net of cash acquired											-381
acquisitions of available-for-sale financial assets											-105
transactions with non-controlling interests, other than dividends											-37
net loss from the held-for-exchange animal health business
operating cash flow before changes in working capital and excluding the held-for-exchange animal health business
net cash from operating activities excluding the held-for-exchange animal health business
net cash from operating activities of the held-for-exchange animal health business
net cash from investing activities excluding the held-for-exchange animal health business
net cash from investing activities of the held-for-exchange animal health business
· to shareholders of sanofi
· to non-controlling interests, excluding bms
transactionswith non-controlling interests, other than dividends
net cash from financing activities excluding the held-for-exchange animal health business
net cash from financing activities of the held-for-exchange animal health business
impact on cash and cash equivalents of the reclassification of the animal health business to “assets held for sale or exchange”
net change in cash and cash equivalents excluding the animal health business
net change in cash and cash equivalents of the animal health business
unrealized (gains)/losses recognized in income
· to equity holders of sanofi
impact of merial cash and cash equivalents
further to the announcement that merial and intervet/schering-plough are to be maintained as separate businesses operating independently, the line items in the statement of cash flows for the comparative periods (2010 and 2009) include cash flows generated by the operating investing and financing activities of merial. the cash and cash equivalents of merial were reported in the balance sheet in assets held for sale or exchange as of december 31, 2009 and 2010.
– net change in cash and cash equivalents excluding merial
– net change in cash and cash equivalents of merial
– net change in cash and cash equivalents including merial
see note c.1. including available-for-sale financial assets. including:
– income tax paid
– interest paid
– interest received
– dividends received from non-consolidated entities
property, plant and equipment, intangible assets, investments in consolidated entities and other non-current financial assets.
non-controlling interests other than bms
acquisitions of investments in consolidated entities, net of cash acquired
Ÿ to shareholders of sanofi
Ÿ to non-controlling interests, excluding bms
impact of the cash and cash equivalents of merial
further to the announcement that merial and intervet/schering-plough are to be maintained as separate businesses operating independently, the line items in the statement of cash flows for the comparative periods (2010) include cash flows generated by the operating investing and financing activities of merial. the cash and cash equivalents of merial were reported in the balance sheet in assets held for sale or exchange as of december 31, 2009, december 31, 2010 and june 30, 2010.
see note c.1. to the financial statements for the year ended december 31, 2010.
including available-for-sale financial assets. including:
– income taxes paid
amounts for issuance of sanofi shares and dividends paid to equity holders of sanofi are reported net of dividends taken in the form of shares, which do not generate cash flows.
arising primarily on the translation of u.s. dollar surplus cash from american subsidiaries transferred to the parent company (sanofi).
net income attributable to equity holders of sanofi-aventis
net income from the held-for-exchange merial business
dividends received from merial
net change in loans and other non-current financial assets
issuance of sanofi-aventis shares
• to shareholders of sanofi-aventis
income tax paid
interest paid
interest received
dividends received from non-consolidated entities
property, plant and equipment, intangible assets, investments in consolidated undertakings and other non-current financial assets.
net income attributable to equity-holders of sanofi-aventis
share of undistributed earnings of associates
impact of workdown of acquired inventories remeasured at fair value
n to equity-holders of sanofi-aventis
n to non-controlling interests
transactions with non-controlling interests other than dividends
additional long-term borrowings
repayments of non-current debt
net change in current debt
net income attributable to equity holders of the company
minority interests, excluding bms
net change in other current assets, financial assets (current) and other current liabilities
• to sanofi-aventis shareholders
• to minority shareholders, excluding bms
repayments of long-term borrowings
net change in short-term borrowings
see note c.1.
unrealized (gains) and losses
acquisitions of property, plant and equipment and intangibles
proceeds from disposals of property, plant and equipment, intangibles and other non-current assets, net of tax
n to sanofi-aventis shareholders
n to minority shareholders, excluding bms
impact of workdown of aventis inventories remeasured at fair value, net of tax
unrealized gains and losses recognized in income
increase/(decrease) in accounts payable and accrued expenses
net change in other current assets, financial assets — current and other current liabilities
net change in other current assets, financial assets – current and other current liabilities
net change in other current assets, financial assets (current) & other current liabilities
acquisitions of property, plant & equipment and intangibles
acquisitions and disposals of treasury shares, net of tax
net income
minority interests other than bms
share of earnings of associates, net of dividend and equivalents received
depreciation and amortization
gains and losses on disposals of non-current assets
unrealized gains and losses recognized in income statement
acquisition of aventis, net of cash acquired
proceeds from disposals of property, plant and equipment, intangibles and other non-current assets
• to minority shareholders other than bms
acquisitions and disposals of treasury shares
minority interests
share in undistributed earnings of equity investees
gains on disposals of fixed assets, net of income taxes
provisions, long-term deferred taxes and other
expensing of research and development and impact of remeasurement of inventories, net of income taxes
dividends received from equity investees
change in other operating assets and liabilities
other acquisitions of investments
proceeds from disposals of fixed assets, net of income taxes
net change in loans, long-term advances and other investing cash flows
capital contribution from minority shareholders
- to sanofi-aventis shareholders
- to minority shareholders of subsidiaries
acquisitions of treasury shares net of disposals, including disposals made in connection with stock options
- decrease in inventories
- decrease in accounts receivable
- increase in accounts payable
- change in other operating assets and liabilities
acquisitions of investments
issuance of shares
dividends paid :
- to sanofi-synthelabo shareholders
acquisitions of treasury shares net of disposal, including disposals made in connection with stock-options plans
- (increase) / decrease in inventories
- (increase)/ decrease in accounts receivable
- increase / (decrease) in accounts payable
issuance of sanofi-synthélabo shares
– to sanofi-synthélabo shareholders
– to minority shareholders of subsidiaries
acquisitions of treasury shares net of disposals, including disposals made in connection with stock option plans
– dividends received from equity investees
– decrease in inventories
– decrease in accounts receivable
– increase in accounts payable
– change in other operating assets and liabilities
total investments
asset disposals and other items
change in borrowings and other items
dividends paid
repurchase of own shares

Sanofi(NASDAQ:SNY)

Sanofi
(NASDAQ:SNY)